Bicycle Therapeutics plc (NASDAQ:BCYC) Receives Consensus Rating of “Moderate Buy” from Brokerages

Bicycle Therapeutics plc (NASDAQ:BCYC) has received an average rating of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $35.25.

A number of analysts recently issued reports on the stock. HC Wainwright decreased their price objective on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating for the company in a report on Monday, December 16th. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. JMP Securities decreased their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a report on Wednesday, December 18th. Stephens assumed coverage on shares of Bicycle Therapeutics in a report on Friday, November 8th. They set an “equal weight” rating and a $25.00 target price on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price target on shares of Bicycle Therapeutics in a research report on Thursday, October 31st.

Insider Activity

In other news, CEO Kevin Lee sold 3,212 shares of the business’s stock in a transaction that occurred on Thursday, October 3rd. The shares were sold at an average price of $22.26, for a total value of $71,499.12. Following the completion of the sale, the chief executive officer now directly owns 380,864 shares in the company, valued at approximately $8,478,032.64. The trade was a 0.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Bros. Advisors Lp Baker acquired 985,397 shares of the business’s stock in a transaction dated Friday, December 13th. The stock was acquired at an average cost of $13.76 per share, with a total value of $13,559,062.72. Following the purchase, the director now directly owns 9,537,643 shares in the company, valued at $131,237,967.68. This represents a 11.52 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have sold 10,840 shares of company stock worth $259,128. 8.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Bicycle Therapeutics

A number of institutional investors have recently made changes to their positions in BCYC. GAMMA Investing LLC boosted its position in Bicycle Therapeutics by 105.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after buying an additional 1,038 shares during the period. L & S Advisors Inc raised its stake in shares of Bicycle Therapeutics by 2.4% during the third quarter. L & S Advisors Inc now owns 59,735 shares of the company’s stock valued at $1,352,000 after acquiring an additional 1,400 shares during the last quarter. Assetmark Inc. purchased a new stake in shares of Bicycle Therapeutics during the third quarter worth about $34,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Bicycle Therapeutics by 69.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock worth $162,000 after purchasing an additional 2,918 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Bicycle Therapeutics by 0.6% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 888,081 shares of the company’s stock worth $17,975,000 after purchasing an additional 4,976 shares during the last quarter. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Stock Performance

NASDAQ:BCYC opened at $14.68 on Monday. Bicycle Therapeutics has a 52 week low of $12.17 and a 52 week high of $28.67. The firm has a 50-day moving average price of $21.83 and a two-hundred day moving average price of $22.49. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -4.46 and a beta of 0.86.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.04. The business had revenue of $2.68 million for the quarter, compared to analyst estimates of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. Bicycle Therapeutics’s quarterly revenue was down 50.0% compared to the same quarter last year. During the same period last year, the company posted ($1.26) earnings per share. As a group, sell-side analysts forecast that Bicycle Therapeutics will post -3.05 earnings per share for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.